<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The IL-12Rbeta2 gene is expressed in human mature B cell subsets but not in transformed B cell lines </plain></SENT>
<SENT sid="1" pm="."><plain>Silencing of this gene may be advantageous to neoplastic B cells </plain></SENT>
<SENT sid="2" pm="."><plain>Our objective was to investigate the mechanism(s) and the functional consequence(s) of IL-12Rbeta2 gene silencing in primary B cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and transformed B cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>Purified <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells from 41 patients with different <z:hpo ids='HP_0011010'>chronic</z:hpo> B cell <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo>, representing the counterparts of the major mature human B cell subsets, tested negative for IL-12Rbeta2 gene expression </plain></SENT>
<SENT sid="4" pm="."><plain>Hypermethylation of a CpG island in the noncoding exon 1 was associated with silencing of this gene in malignant B cells </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with the DNA methyltransferase inhibitor <z:chebi fb="0" ids="50131">5-Aza-2'-deoxycytidine</z:chebi> restored IL-12Rbeta2 mRNA expression in primary neoplastic B cells that underwent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> following exposure to human recombinant IL-12 (hrIL-12) </plain></SENT>
<SENT sid="6" pm="."><plain>hrIL-12 inhibited proliferation and increased the apoptotic rate of IL-12Rbeta2-transfected B cell lines in vitro </plain></SENT>
<SENT sid="7" pm="."><plain>Finally, hrIL-12 strongly reduced the tumorigenicity of IL-12Rbeta2-transfected Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> RAJI cells in <z:mp ids='MP_0002536'>SCID</z:mp>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOD</z:e> mice through antiproliferative and proapoptotic effects, coupled with neoangiogenesis inhibition related to human IFN-gamma-independent induction of hMig/CXCL9 </plain></SENT>
<SENT sid="8" pm="."><plain>The IL-12Rbeta2 gene acts as <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor in <z:hpo ids='HP_0011010'>chronic</z:hpo> B cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, and IL-12 exerts direct antitumor effects on IL-12Rbeta2-expressing neoplastic B cells </plain></SENT>
</text></document>